Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP

Madison Asset Management LLC purchased a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,107,175 shares of the company’s stock, valued at approximately $13,654,000. Madison Asset Management LLC owned about 5.74% of Armata Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ARMP. BlackRock Inc. purchased a new stake in shares of Armata Pharmaceuticals during the second quarter worth about $3,629,000. Deutsche Bank AG acquired a new stake in Armata Pharmaceuticals in the 2nd quarter worth approximately $78,000. Bank of New York Mellon Corp acquired a new stake in Armata Pharmaceuticals in the 2nd quarter worth approximately $193,000. Bank of America Corp DE boosted its stake in Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock worth $120,000 after purchasing an additional 8,198 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in Armata Pharmaceuticals during the 1st quarter worth approximately $760,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Stock Performance

Shares of ARMP opened at $5.07 on Thursday. The stock has a 50-day moving average of $5.41 and a two-hundred day moving average of $8.08. Armata Pharmaceuticals, Inc. has a one year low of $2.40 and a one year high of $16.34. The stock has a market cap of $188.50 million, a P/E ratio of -0.67 and a beta of 1.30.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.17. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%.The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $0.40 million. Analysts predict that Armata Pharmaceuticals, Inc. will post 0.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.